Research programme: chimeric antigen receptor-targeted therapies - Novartis/University of Pennsylvania

Drug Profile

Research programme: chimeric antigen receptor-targeted therapies - Novartis/University of Pennsylvania

Alternative Names: Adoptive T-cell immunotherapies - University of Pennsylvania/Novartis; CAR immunotherapies - University of Pennsylvania/Novartis

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer Novartis; University of Pennsylvania
  • Class CAR-T cell therapies; Gene therapies
  • Mechanism of Action Immunostimulants; T-cell receptor gene modulators; T-lymphocyte differentiation antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Oct 2014 Oxford BioMedica and Novartis enter into a process development and manufacturing collaboration for the LentiVector® technology, and tisagenlecleucel-T and other CAR T cell therapies
  • 31 Jul 2013 Life Technologies and Novartis enter a long-term supply and license agreement for Dynabead®CD3/CD28 CTS™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top